Tom J C Ruffles1,2, Julie M Marchant1, Ian B Masters1, Stephanie T Yerkovich3, Danielle F Wurzel4, Peter G Gibson5, Greta Busch1, Katherine J Baines5, Jodie L Simpson5, Heidi C Smith-Vaughan6, Susan J Pizzutto6, Helen M Buntain1, Gregory Hodge7, Sandra Hodge7, John W Upham8, Anne B Chang1,6. 1. Department of Respiratory and Sleep Medicine, Queensland Children's Hospital, Centre for Children's Health Research, Queensland University of Technology, Brisbane, QLD, Australia. 2. Academic Department of Paediatrics, The Royal Alexandra Children's Hospital, Brighton and Sussex Medical School, Brighton, UK. 3. The School of Medicine, The University of Queensland, Brisbane, QLD, Australia. 4. Infection and Immunity, Murdoch Children's Research Institute; Respiratory and Sleep Medicine, The Royal Children's Hospital, Melbourne, VIC, Australia. 5. Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute, The University of Newcastle, Newcastle, NSW, Australia. 6. Child Health Division, Menzies School of Health Research, Darwin, NT, Australia. 7. The Chronic Inflammatory Lung Disease Research Laboratory, Department of Thoracic Medicine, Royal Adelaide Hospital and School of Medicine, University of Adelaide, Adelaide, SA, Australia. 8. The University of Queensland Diamantina Institute and Princess Alexandra Hospital, Brisbane, QLD, Australia.
Abstract
BACKGROUND AND OBJECTIVE: Long-term data on children with PBB has been identified as a research priority. We describe the 5-year outcomes for children with PBB to ascertain the presence of chronic respiratory disease (bronchiectasis, recurrent PBB and asthma) and identify the risk factors for these. METHODS: Prospective cohort study was undertaken at the Queensland Children's Hospital, Brisbane, Australia, of 166 children with PBB and 28 controls (undergoing bronchoscopy for symptoms other than chronic wet cough). Monitoring was by monthly contact via research staff. Clinical review, spirometry and CT chest were performed as clinically indicated. RESULTS: A total of 194 children were included in the analysis. Median duration of follow-up was 59 months (IQR: 50-71 months) post-index PBB episode, 67.5% had ongoing symptoms and 9.6% had bronchiectasis. Significant predictors of bronchiectasis were recurrent PBB in year 1 of follow-up (ORadj = 9.6, 95% CI: 1.8-50.1) and the presence of Haemophilus influenzae in the BAL (ORadj = 5.1, 95% CI: 1.4-19.1). Clinician-diagnosed asthma at final follow-up was present in 27.1% of children with PBB. A significant BDR (FEV1 improvement >12%) was obtained in 63.5% of the children who underwent reversibility testing. Positive allergen-specific IgE (ORadj = 14.8, 95% CI: 2.2-100.8) at baseline and bronchomalacia (ORadj = 5.9, 95% CI: 1.2-29.7) were significant predictors of asthma diagnosis. Spirometry parameters were in the normal range. CONCLUSION: As a significant proportion of children with PBB have ongoing symptoms at 5 years, and outcomes include bronchiectasis and asthma, they should be carefully followed up clinically. Defining biomarkers, endotypes and mechanistic studies elucidating the different outcomes are now required.
BACKGROUND AND OBJECTIVE: Long-term data on children with PBB has been identified as a research priority. We describe the 5-year outcomes for children with PBB to ascertain the presence of chronic respiratory disease (bronchiectasis, recurrent PBB and asthma) and identify the risk factors for these. METHODS: Prospective cohort study was undertaken at the Queensland Children's Hospital, Brisbane, Australia, of 166 children with PBB and 28 controls (undergoing bronchoscopy for symptoms other than chronic wet cough). Monitoring was by monthly contact via research staff. Clinical review, spirometry and CT chest were performed as clinically indicated. RESULTS: A total of 194 children were included in the analysis. Median duration of follow-up was 59 months (IQR: 50-71 months) post-index PBB episode, 67.5% had ongoing symptoms and 9.6% had bronchiectasis. Significant predictors of bronchiectasis were recurrent PBB in year 1 of follow-up (ORadj = 9.6, 95% CI: 1.8-50.1) and the presence of Haemophilus influenzae in the BAL (ORadj = 5.1, 95% CI: 1.4-19.1). Clinician-diagnosed asthma at final follow-up was present in 27.1% of children with PBB. A significant BDR (FEV1 improvement >12%) was obtained in 63.5% of the children who underwent reversibility testing. Positive allergen-specific IgE (ORadj = 14.8, 95% CI: 2.2-100.8) at baseline and bronchomalacia (ORadj = 5.9, 95% CI: 1.2-29.7) were significant predictors of asthma diagnosis. Spirometry parameters were in the normal range. CONCLUSION: As a significant proportion of children with PBB have ongoing symptoms at 5 years, and outcomes include bronchiectasis and asthma, they should be carefully followed up clinically. Defining biomarkers, endotypes and mechanistic studies elucidating the different outcomes are now required.
Authors: Jennifer L Perret; Danielle Wurzel; E Haydn Walters; Adrian J Lowe; Caroline J Lodge; Dinh S Bui; Bircan Erbas; Gayan Bowatte; Melissa A Russell; Bruce R Thompson; Lyle Gurrin; Paul S Thomas; Garun Hamilton; John L Hopper; Michael J Abramson; Anne B Chang; Shyamali C Dharmage Journal: BMJ Open Respir Res Date: 2022-06
Authors: Kerry-Ann F O'Grady; Juliana Mahon; Daniel Arnold; Keith Grimwood; Kerry K Hall; Vikas Goyal; Julie M Marchant; Natalie Phillips; Jason Acworth; Alex King; Mark Scott; Anne B Chang Journal: J Clin Med Date: 2021-12-07 Impact factor: 4.241
Authors: Anne B Chang; Maree Toombs; Mark D Chatfield; Remai Mitchell; Siew M Fong; Michael J Binks; Heidi Smith-Vaughan; Susan J Pizzutto; Karin Lust; Peter S Morris; Julie M Marchant; Stephanie T Yerkovich; Hannah O'Farrell; Paul J Torzillo; Carolyn Maclennan; David Simon; Holger W Unger; Hasthika Ellepola; Jens Odendahl; Helen S Marshall; Geeta K Swamy; Keith Grimwood Journal: Front Pediatr Date: 2022-01-17 Impact factor: 3.418